Metastatic Castration-Resistant Prostate Cancer
common.study.values.description
“An Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies”
The purpose of this study is to assess the efficacy, safety, and pharmacokinetics of niraparib in men with metastatic castration resistant prostate cancer (mCRPC) and deoxyribonucleic acid (DNA) repair anomalies.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Niraparib
Participants will receive 300 mg niraparib (3 capsules*100 mg) orally once daily.
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase 2 Efficacy and Safety Study of Niraparib in Men With Metastatic Castration-Resistant Prostate Cancer and DNA-Repair Anomalies
common.study.values.clinical-trial-id
NCT02854436
participant.views.study.view.id
9av58e
